Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Warfarin with PEX168 in Healthy Subjects
NCT02461914Phase 1Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Aug 2015
- Primary completion
- Dec 2015
- Modality
- Peptides
01
Overview
Phase 1, open-label, single-arm trial of polyethylene glycol loxenatide in type 2 diabetes mellitus (T2DM), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Plasma concentrations of warfarin. Started Aug 2015; status: completed.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02461914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02461914.